Country: United States
Language: English
Source: NLM (National Library of Medicine)
BRIMONIDINE TARTRATE (UNII: 4S9CL2DY2H) (BRIMONIDINE - UNII:E6GNX3HHTE)
Regimed Medical
BRIMONIDINE TARTRATE
BRIMONIDINE 2.0 mg in 1 mL
OPHTHALMIC
PRESCRIPTION DRUG
Brimonidine Tartrate Ophthalmic Solution is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The IOP lowering efficacy of Brimonidine Tartrate Ophthalmic Solution diminishes over time in some patients. This loss of effect appears with a variable time of onset in each patient and should be closely monitored. Brimonidine Tartrate Ophthalmic Solution is contraindicated in patients with hypersensitivity to brimonidine tartrate or any component of this medication. It is also contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy.
Brimonidine Tartrate Ophthalmic Solution, 0.2% is supplied in white opaque plastic dropper bottles as followss:
Abbreviated New Drug Application
BRIMONIDINE TARTRATE- BRIMONIDINE TARTRATE SOLUTION/ DROPS REGIMED MEDICAL ---------- BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION, 0.2% R ONLY DESCRIPTION Brimonidine Tartrate Ophthalmic Solution, 0.2% is a relatively selective alpha-2 adrenergic agonist for ophthalmic use. The chemical name brimonidine tartrate is 5-bromo-6 (2-imidazolidinylideneamino) quinoxaline L-tartrate. It is a white to slightly yellowish powder. In solution, brimonidine tartrate has a clear, grennish-yellow color. It has a molecular weight of 442.24 as the tartrate salt and is water soluble (34 mg/mL). The molecular formula is C H BrN •C H O ; the structural formula is: Brimonidine Tartrate Ophthalmic Solution, 0.2% is a sterile ophthalmic solution. Each mL of Brimonidine Tartrate Solution contains: ACTIVE: Brimonidine Tartrate 2 mg (equivalent to 1.32 mg as brimonidine free base). PRESERVATIVE: Benzalkonium Chloride (0.05 mg) INACTIVES: Citric Acid, Polyvinyl Alcohol, Sodium Citrate; Hydrochloric Acid and/or Sodium Hydroxide may be added to adjust pH (5.6 to 6.6), and Water for Injection. CLINICAL PHARMACOLOGY MECHANISM OF ACTION Brimonidine Tartrate Ophthalmic Solution is an alpha adrenergic receptor agonist. It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. PHARMACOKINETICS After ocular administration of a 0.2% solution, plasma concentrations peaked within 1 to 4 hours and declined with a systemic half-life of approximately 3 hours. In humans, systemic metabolism of brimonidine is extensive. It is metabolized primarily by the liver. Urinary excretion is the major route of elimination of the drug and its metabolites. Approximately 87% of an orally administered radioactive dose was eliminated within 120 hours, with 74% found in the urine. CLINICAL EVALUATIONS Elevated IOP presents a major risk factor in glaucomatous field loss. Th Read the complete document